₹1,482.2 crore in the second quarter ended September 30, led by the US generics market. The company had posted a consolidated profit after tax of ₹1,114.2 crore in the same quarter a year ago, Dr Reddy's Laboratories Ltd (DRL) said in a regulatory filing.
Read more on livemint.com